Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

Core Insights - Insmed Incorporated will host a conference call on May 28, 2024, at 8:00 am ET to discuss topline results from the ASPEN study, a Phase 3 trial assessing brensocatib for non-cystic fibrosis bronchiectasis [1] - A press release with topline results will be issued at approximately 6:30 am ET on the same day [1] Company Overview - Insmed is a global biopharmaceutical company focused on transforming the lives of patients with serious and rare diseases [4] - The company has a first-in-disease therapy approved in the U.S., Europe, and Japan for a chronic lung disease and is developing a pipeline targeting unmet needs in inflammatory diseases and rare pulmonary disorders [4] - Insmed is advancing research in various technologies, including AI-driven protein engineering and gene therapy, and is headquartered in Bridgewater, New Jersey [4]